NCT03760575View on ClinicalTrials.gov

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Mesotheliomas Pleural
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200mg via IV infusion every 3 weeks for 2 cycles 3 pre-surgery, for 4 cycles post-surgery and then every 3 weeks during maintenance.

PROCEDURE

Indocyanine Green (ICG) Image-Guided Surgery

Standard surgery with image guided resection.

DRUG

Cisplatin

75 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.

DRUG

Pemetrexed

500 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.

Trial Locations (1)

19104

RECRUITING

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER